Divi's Laboratories Limited held its Q4 FY26 earnings conference call on May 23, 2026, at 14:30 hrs (IST). The transcript was submitted to the National Stock Exchange of India Limited and BSE Limited on May 29, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Q4 FY26 Results:

  • Consolidated Total Income: ₹2,986 crores
  • Profit Before Tax: ₹963 crores (compared to ₹864 crores in Q4 FY25)
  • Profit After Tax: ₹751 crores
  • Forex Gain: ₹90 crores

Full Year FY26 Results:

  • Consolidated Total Income: ₹11,067 crores (compared to ₹9,712 crores in FY25)
  • Profit Before Tax: ₹3,388 crores (after accounting for ₹74 crores impact of Labour Codes)
  • Profit After Tax: ₹2,568 crores (compared to ₹2,191 crores in FY25)
  • Forex Gain: ₹211 crores (compared to ₹48 crores in FY25)

Key Operational Metrics

  • Material consumption stood at 38.8% of sales revenue (vs. 39.8% in previous year)
  • Exports contributed 89% of total sales revenue
  • Europe and United States together accounted for 74% of export revenue
  • Product mix: Generics 45%, Custom Synthesis 55%
  • Constant currency growth: 6.82%
  • Nutraceuticals business revenue: ₹946 crores (vs. ₹781 crores in FY25)

Capital Expenditure and Balance Sheet

  • Capitalized assets worth ₹1,544 crores during FY26 (approximately ₹800 crores capitalized in Q4)
  • Capital Work in Progress as of March 31, 2026: ₹2,113 crores
  • Cash and Cash equivalents: ₹3,414 crores
  • Receivables: ₹2,984 crores
  • Inventories: ₹3,954 crores

Business Segment Updates

Generic Business: Volumes remained stable through the quarter and full year with steady demand across markets, though pricing environment remains competitive.

Custom Synthesis Segment: Customer engagement remained strong with active project pipeline. The company is positioned to participate meaningfully in opportunities as molecules progress through development to near commercialization.

Peptide Business: The company continues to deepen capabilities with strategic investments in both solid phase and liquid phase synthesis capabilities. Several fragments have been successfully validated with more in the pipeline.

Manufacturing Operations: Unit 3 facility is now playing an increasingly important role in overall operations by supporting backward integration capacity. Select activities have been transferred from Unit 1 and Unit 2, freeing up GMP space and enabling better capacity optimization.

Supply Chain and Logistics Challenges

The company faced significant supply chain disruptions due to geopolitical tensions in West Asia, which created:

  • Congestion at key ports
  • Extended transit timelines
  • Operational uncertainty
  • Force majeure clauses invoked by suppliers
  • Considerable increase in freight rates across ocean and air transportation
  • Container and tank availability constraints

Despite these challenges, critical raw materials and solvents remained broadly manageable due to proactive procurement planning and strengthened sourcing ecosystem. The company is currently focusing material availability on a quarterly basis.

Labour Code Impact

Pursuant to the notification of the four Labour Codes effective from November 21, 2025, the company assessed a one-time incremental impact of ₹74 crores towards employee benefits during and post-employment. This has been fully provided for and disclosed as an exceptional item.

Management Guidance and Outlook

  • Double-digit revenue growth expected for FY27
  • Margin outlook remains stable despite challenges
  • Freight-related cost pressures expected to continue in near term
  • Continued investment in technology platforms including continuous flow chemistry, biocatalysis, and automation

Project Pipeline and Future Opportunities

The management discussed several ongoing projects:

  • Three dedicated capacity projects at various stages of validation
  • Contrast media business (Iodine-based) already in commercial sales with major players
  • Gadolinium compounds still at qualification stage (Phase II, Phase III)
  • Peptide business with several 3,000-liter SPPS capacities targeting global leadership
  • The company expects commercialization of dedicated projects around 2027, subject to regulatory approvals

Q&A Highlights

Analysts questioned management on:

  • Raw material availability challenges, particularly methanol and other solvents
  • Impact of GLP-1 opportunity shifts
  • Capex plans for FY27 (expected to be constant unless major new projects emerge)
  • Margin sustainability and drivers
  • Supply chain cost pass-through capabilities
  • Inventory management strategies
  • Regulatory processes for new facilities
  • Revenue recognition timelines for capex investments (typically 2-year cycle)